Delving into the Latest Updates on CYT-004-MelQbG10 with Synapse

Overview

Basic Info

Drug Type

Virus-like particle vaccine, Therapeutic vaccine

Synonyms

Melan-A VLP vaccine, Melanoma virus-like particle vaccine

+ [1]

Target

MAGEA1

Mechanism

MAGEA1 modulators(Melanoma-associated antigen 1 modulators)

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

HLA-A2 Positive Non-Small Cell Lung CancerMalignant melanoma stage IV

Originator Organization

Kuros Biosciences Ltd.

Active Organization-

Inactive Organization

Cytos Biotechnology AG

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Virus-like particles (VLPs) are self-assembled protein nanoparticles with repetitive antigen epitopes, which can stimulate immune response and do not contain viral genetic materials. VLPs has important research value and application potential in vaccine development, targeted drug delivery and bioengineering materials. In this review, the mechanism of VLPs vaccine induced immune responses is discussed. The existing VLPs expression systems are summarized. The research progress of VLPs vaccine in prevention and treatment of virus infection are summarized. This review provides general reference and guidance for the design and development of antiviral VLPs vaccine.

01 May 2024·Molecular Biotechnology

Preclinical Evaluation of virus-like particle Vaccine Against Carbonic Anhydrase IX Efficacy in a Mouse Breast Cancer Model System

Article

Author: Tārs, Kaspars ; Akopjana, Ināra ; Kalniņa, Zane ; Kazāks, Andris ; Skeltona, Vendija ; Liekniņa, Ilva

Carbonic anhydrase IX (CAIX) is a cancer-associated membrane protein frequently overexpressed in hypoxic solid tumours leading to enhanced tumour cell survival and invasion, and it has been proposed to be an attractive tumour-specific molecule for antibody-mediated targeting. This study aimed to generate a virus-like particle (VLP)-based CAIX vaccine candidate and evaluate its efficacy in a mouse model of breast cancer. The prototype murine vaccine was developed based on the ssRNA bacteriophage Qbeta VLPs with chemically coupled murine CAIX protein catalytic domains on their surfaces. The vaccine was shown to efficiently break the natural B cell tolerance against autologous murine CAIX and to induce high-titre Th1-oriented IgG responses in the BALB/c mice. This vaccine was tested in a therapeutic setting by using a triple-negative breast cancer mouse model system comprising 4T1, 4T1-Car9^KI and 4T1-Car9^KO cells, the latter representing positive and negative controls for murine CAIX production, respectively. The humoural immune responses induced in tumour-bearing animals were predominantly of Th1-type and higher anti-mCAIXc titres correlated with slower growth and lung metastasis development of 4T1 tumours constitutively expressing mCAIX in vivo in the syngeneic host.

01 Oct 2023·Poultry Science

Efficacy of a plant-produced infectious bronchitis virus-like particle vaccine in specific pathogen-free chickens

Article

Author: Abolnik, Celia ; Smith, Peter ; O'Kennedy, Martha M ; Sepotokele, Kamogelo M ; Wandrag, Daniel B R ; Hayes, Michaela C

Infectious bronchitis (IB) Gammacoronavirus causes a highly contagious respiratory disease in chickens that is listed by the World Organisation for Animal Health (WOAH). Its high mutation ability has resulted in numerous variants against which the commercially available live or recombinant vaccines singly offer limited protection. Agrobacterium-mediated transient expression in Nicotiana benthamiana (tobacco) plants was used here to produce a virus-like particle (VLP) vaccine expressing a modified full-length IBV spike (S) protein of a QX-like IB variant. In a challenge study with the homologous live IB QX-like virus, VLP-vaccinated birds produced S protein-specific antibodies comparable to those produced by live-vaccinated birds seroconverting with mean geometric titers of 6.8 and 7.2 log₂, respectively. The VLP-vaccinated birds had reduced oropharyngeal and cloacal viral shedding compared to an unvaccinated challenged control and were more protected against tracheal ciliostasis than the live-vaccinated birds. While the results appeared similar, plant-produced IB VLPs are safer, more affordable, easier to produce and update to antigenically match any emerging IB variant, making them a more suitable alternative to IBV control than live-attenuated vaccines.

100 Deals associated with CYT-004-MelQbG10

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HLA-A2 Positive Non-Small Cell Lung Cancer	Phase 2	DE	Cytos Biotechnology AG	24 Mar 2006
Malignant melanoma stage IV	Phase 2	DE	Cytos Biotechnology AG	24 Mar 2006